Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer

Despite widespread administration of programmed death receptor 1 (PD-1) pathway inhibitors among individuals with NSCLC, little is known about the safety and activity of these agents among human immunodeficiency virus (HIV) - infected patients since this population has largely been excluded from imm...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of thoracic oncology Vol. 13; no. 7; p. 1037
Main Authors:	Ostios-Garcia, Lorena, Faig, Jennifer, Leonardi, Giulia C, Adeni, Anika E, Subegdjo, Safiya J, Lydon, Christine A, Rangachari, Deepa, Huberman, Mark S, Sehgal, Kartik, Shea, Meghan, VanderLaan, Paul A, Cheng, Matthew P, Marty, Francisco M, Hammond, Sarah P, Costa, Daniel B, Awad, Mark M
Format:	Journal Article
Language:	English
Published:	United States 01-07-2018
Subjects:	Adult Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use B7-H1 Antigen - antagonists & inhibitors Carcinoma, Non-Small-Cell Lung - complications Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - virology Female Follow-Up Studies HIV - drug effects HIV Infections - complications HIV Infections - drug therapy HIV Infections - virology Humans Lung Neoplasms - complications Lung Neoplasms - drug therapy Lung Neoplasms - virology Male Middle Aged Nivolumab - administration & dosage Prognosis Retrospective Studies Survival Rate Pembrolizumab HIV Immunotherapy Lung cancer Nivolumab PD-L1 PD-1
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!